Ginwa Enterprise Group Inc (600080) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Ginwa Enterprise Group Inc stock ¥0.76, price ¥3.93, that is 80.7% below the price, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Ginwa Enterprise Group Inc
600080 · SHGOur calculation puts a fair price 81% below what the stock costs today.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range ¥3.90 – ¥10.87 · fair‑value band ¥0.5300 – ¥0.9900 · the ¥3.93 price screens above the ¥0.7600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.
Every Wednesday you see whether Ginwa Enterprise Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Ginwa Enterprise (Group) Inc. researches, develops, produces, markets, and sells traditional Chinese medicines, biological drugs, and chemical drugs primarily in China.
Show moreShow less
The company offers a range of orthopaedics, immunity, children, and general medicines in various dosage forms, including tablets, capsules, granules, powders, mixtures, oral solutions, syrups, and external solutions. It is also involved in the pharmaceutical logistics activities.
The company was founded in 1996 and is headquartered in Xi'an, China.
Stock analysis
Ginwa Enterprise Group Inc (600080) currently trades at ¥3.93, while our model-based Fair Value estimate is ¥0.7600, 81% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Economic Profit group reads highest at a median of ¥1.62 per share, and 1 of the 15 models we run sit above the ¥3.93 price.
Bear case: the Dividend Discount group reads lowest at ¥0.4000, and 14 of the 15 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥0.5300 (bear) to ¥0.9900 (bull), the price of ¥3.93 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Ginwa Enterprise Group Inc reported revenue of 544M CNY in FY2025 versus 534M CNY in FY2021, a compound +0.5%/yr. Reported net income was 15.6M CNY in FY2025.
Key figures
Market cap 1.5B CNY (≈ $220M) Micro · P/E ratio 131.0 · P/S ratio 2.71 · EPS (TTM) ¥0.0300 · Dividend yield 0.8% · Net margin 1.9% · Return on equity 0.6% · Return on assets (EBIT) 0.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (medium confidence).
What moves the price
The share trades about 57% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −81%, 600080 screens richer than that median.
Fair Value models
All 15 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
600080 screens overvalued: fair value 81% below the price. Compare with Merck KGaA →
Compare Ginwa Enterprise Group Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EBIT margin by industry
- P/S ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Chinese Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $79.40 | $113.53 | +43% | vs 600080 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥50.43 | ¥55.21 | +9% | vs 600080 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,860 | ₹1,947 | +5% | vs 600080 |
| Haleon plc HLN | $9.14 | $8.61 | −6% | vs 600080 |
| Merck KGaA MRK | €148.75 | €109.18 | −27% | vs 600080 |
| Galderma Group GALD | CHF 191.75 | CHF 109.86 | −43% | vs 600080 |
| Takeda Pharmaceutical Company TAK | $21.02 | $11.31 | −46% | vs 600080 |
| Teva Pharmaceutical Industries Limited TEVA | $42.61 | $20.74 | −51% | vs 600080 |
| Sandoz Group SDZ | CHF 83.78 | CHF 39.70 | −53% | vs 600080 |
| Divi's Laboratories Limited DIVISLAB | ₹10,321 | ₹1,567 | −85% | vs 600080 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Ginwa Enterprise Group Inc (600080) overvalued or undervalued?
What is the fair value of 600080?
What is the quality score of 600080?
What is the price target for Ginwa Enterprise Group Inc (600080)?
What is the Ginwa Enterprise Group Inc stock forecast for 2026?
What is the revenue of Ginwa Enterprise Group Inc (600080)?
Does Ginwa Enterprise Group Inc pay a dividend?
How much is the dividend of Ginwa Enterprise Group Inc (600080)?
What is the intrinsic value of Ginwa Enterprise Group Inc (600080)?
Is Ginwa Enterprise Group Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 600080?
How much is Ginwa Enterprise Group Inc worth?
What do the bullish and bearish scenarios say about 600080?
What is the P/E ratio of 600080?
How solid is the balance sheet of Ginwa Enterprise Group Inc (600080)?
How far is 600080 from its 52-week high?
Which stocks are comparable to Ginwa Enterprise Group Inc?
Is Ginwa Enterprise Group Inc stock attractive at the current price?
How is the fair value of 600080 calculated?
Is it still worth investing in stocks now?
What is the share price of Ginwa Enterprise Group Inc (600080)?
What should I pay attention to with Ginwa Enterprise Group Inc right now?
Key figures of Ginwa Enterprise Group Inc
How large is the market capitalisation of Ginwa Enterprise Group Inc (600080)?
What is the P/S ratio of Ginwa Enterprise Group Inc (600080)?
What are the earnings per share of Ginwa Enterprise Group Inc (600080)?
What is the dividend yield of Ginwa Enterprise Group Inc (600080)?
What is the net margin of Ginwa Enterprise Group Inc (600080)?
What is the return on equity of Ginwa Enterprise Group Inc (600080)?
What is the EBIT return on assets of Ginwa Enterprise Group Inc (600080)?
What is the operating margin of Ginwa Enterprise Group Inc (600080)?
How fast is revenue growing at Ginwa Enterprise Group Inc (600080)?
How fast are earnings growing at Ginwa Enterprise Group Inc (600080)?
How much free cash flow does Ginwa Enterprise Group Inc (600080) generate?
How much net cash does Ginwa Enterprise Group Inc (600080) hold?
Watch Ginwa Enterprise Group Inc in the live analysis
One click puts Ginwa Enterprise Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.